Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at Needham & Company LLC in a report issued on Monday,Benzinga reports. They presently have a $320.00 target price on the biopharmaceutical company's stock. Needham & Company LLC's target price suggests a potential upside of 23.90% from the company's previous close.

ALNY has been the subject of a number of other reports. HC Wainwright restated a "buy" rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Bank of America raised their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a report on Monday, October 14th. TD Cowen upped their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Sanford C. Bernstein lowered their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $298.61.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded up $20.29 during trading hours on Monday, reaching $258.27. The stock had a trading volume of 1,224,350 shares, compared to its average volume of 654,079. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market capitalization of $33.31 billion, a PE ratio of -98.58 and a beta of 0.34. The company's 50-day moving average is $248.88 and its two-hundred day moving average is $259.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the firm posted $1.15 earnings per share. The firm's quarterly revenue was down 33.3% on a year-over-year basis. Research analysts expect that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares in the company, valued at $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock worth $2,540,455 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in ALNY. Geode Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company's stock valued at $589,209,000 after purchasing an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company's stock valued at $134,035,000 after buying an additional 16,756 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company's stock valued at $97,200,000 after buying an additional 100,000 shares during the last quarter. Swiss National Bank increased its holdings in Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company's stock worth $103,246,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its stake in Alnylam Pharmaceuticals by 25.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company's stock valued at $85,889,000 after acquiring an additional 63,385 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.